Hyzaar: Comprehensive Blood Pressure Control in One Tablet
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.75 | $52.44 (0%) | 🛒 Add to cart |
| 60 | $1.51 | $104.88 $90.76 (13%) | 🛒 Add to cart |
| 90 | $1.43 | $157.31 $129.08 (18%) | 🛒 Add to cart |
| 120 | $1.39 | $209.75 $166.39 (21%) | 🛒 Add to cart |
| 180 | $1.35 | $314.63 $243.03 (23%) | 🛒 Add to cart |
| 270 | $1.33 | $471.94 $357.99 (24%) | 🛒 Add to cart |
| 360 | $1.32
Best per pill | $629.26 $473.96 (25%) | 🛒 Add to cart |
Hyzaar represents a significant advancement in antihypertensive therapy, combining two well-established pharmacological agents into a single, convenient tablet. This fixed-dose combination medication contains losartan potassium, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Designed for patients whose blood pressure remains uncontrolled with monotherapy, Hyzaar works through complementary mechanisms to provide superior blood pressure reduction compared to either component alone. Its dual-action approach targets both the renin-angiotensin-aldosterone system and volume regulation, offering clinicians an effective tool for managing hypertension while potentially improving patient adherence through simplified dosing regimens.
Features
- Contains 50 mg losartan potassium and 12.5 mg hydrochlorothiazide per tablet
- Film-coated, oval-shaped tablets with MSD 942 imprint
- Available in blister packs of 14, 28, or 98 tablets
- Combination angiotensin II receptor blocker and thiazide diuretic
- Once-daily dosing regimen
- Manufactured under strict quality control standards
- Temperature-stable formulation
Benefits
- Provides superior blood pressure control compared to monotherapy
- Reduces cardiovascular risk associated with uncontrolled hypertension
- Decreases the pill burden for patients requiring multiple antihypertensive agents
- Offers complementary mechanisms of action for enhanced efficacy
- May improve medication adherence through simplified dosing
- Demonstrates proven safety profile in clinical trials
Common use
Hyzaar is primarily indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide monotherapy. It may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Clinical studies have demonstrated its effectiveness across various patient populations, including those with isolated systolic hypertension and patients with type 2 diabetes and hypertension. The combination therapy is particularly beneficial for patients who require additional blood pressure reduction beyond what can be achieved with single-agent therapy.
Dosage and direction
The usual recommended dose of Hyzaar is one tablet (50 mg losartan/12.5 mg hydrochlorothiazide) taken orally once daily. The dosage may be increased to two tablets once daily if blood pressure remains uncontrolled after 2-3 weeks of therapy. The maximum recommended daily dose is 100 mg losartan and 25 mg hydrochlorothiazide. Tablets should be swallowed whole with a glass of water, preferably at the same time each day to maintain consistent blood levels. Dose titration should be based on individual patient response and tolerability. Patients should be regularly monitored during dosage adjustments.
Precautions
Patients taking Hyzaar should undergo periodic monitoring of blood pressure, renal function, and serum electrolytes. Special caution is required in patients with impaired renal function, as hydrochlorothiazide may precipitate azotemia. Electrolyte imbalances, particularly hypokalemia, hypomagnesemia, and hyponatremia, may occur and require monitoring. Patients with hepatic impairment should be closely supervised due to potential alterations in losartan metabolism. Those with history of allergies or bronchial asthma may be at increased risk of adverse reactions. Sun exposure should be limited due to possible photosensitivity reactions associated with thiazide diuretics.
Contraindications
Hyzaar is contraindicated in patients with known hypersensitivity to losartan, hydrochlorothiazide, or any component of the formulation. It must not be used in patients with anuria or severe renal impairment (creatinine clearance <30 mL/min). The medication is contraindicated in patients with refractory hypokalemia, hypercalcemia, or symptomatic hyperuricemia. Use is prohibited during pregnancy, particularly in the second and third trimesters, due to potential fetal harm. Concomitant use with aliskiren in patients with diabetes is contraindicated.
Possible side effects
Common adverse reactions include dizziness (3.5%), upper respiratory infection (2.1%), cough (2.1%), and fatigue (2.0%). Less frequent side effects may include orthostatic hypotension, gastrointestinal disturbances, muscle cramps, and rash. Serious but rare adverse effects include angioedema, hepatotoxicity, pancreatitis, and blood dyscrasias. Hydrochlorothiazide component may cause photosensitivity, electrolyte imbalances, and hyperglycemia. Losartan may rarely cause hepatic enzyme elevations. Patients should report any persistent or severe symptoms to their healthcare provider promptly.
Drug interaction
Hyzaar may interact with several medication classes. Concomitant use with other antihypertensive agents may potentiate blood pressure lowering effects. NSAIDs may reduce the antihypertensive efficacy and increase renal impairment risk. Lithium levels may increase when used with thiazide diuretics. Potassium-sparing diuretics or potassium supplements may lead to hyperkalemia. Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension. Diabetic medications may require adjustment due to potential hyperglycemic effects of hydrochlorothiazide. Monitoring is recommended when used with digoxin or warfarin.
Missed dose
If a dose of Hyzaar is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistent daily administration is important for maintaining blood pressure control. Patients should establish routines to improve adherence, such as taking the medication at the same time each day or using pill organizers.
Overdose
Hyzaar overdose may manifest as hypotension, tachycardia, bradycardia, dizziness, decreased urinary output, and electrolyte imbalances. Losartan overdose may cause hypotension and tachycardia, while hydrochlorothiazide overdose may lead to electrolyte disturbances, dehydration, and gastrointestinal symptoms. Management involves supportive care with volume expansion with normal saline for hypotension. Gastric lavage may be considered if ingestion was recent. Electrolyte abnormalities should be corrected appropriately. Hemodialysis is not effective for removing losartan but may help correct electrolyte imbalances from hydrochlorothiazide. Patients should seek immediate medical attention if overdose is suspected.
Storage
Hyzaar tablets should be stored at controlled room temperature (20-25°C or 68-77°F) in their original container. Protect from light and moisture. Keep the container tightly closed and out of reach of children. Do not store in bathroom cabinets where humidity levels may fluctuate. Tablets should not be used beyond the expiration date printed on the packaging. Proper storage conditions help maintain drug stability and efficacy throughout the shelf life.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Hyzaar is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual patient responses may vary, and treatment decisions should be based on professional medical judgment. Patients should not adjust their dosage or discontinue medication without consulting their physician. The complete prescribing information contains additional important safety information.
Reviews
Clinical studies demonstrate that Hyzaar provides effective blood pressure control in approximately 70-80% of patients who respond inadequately to monotherapy. Many patients report satisfaction with the convenience of combination therapy and improved adherence compared to multiple separate medications. Healthcare providers appreciate the complementary mechanism of action and the ability to achieve target blood pressure goals more efficiently. Some patients note initial dizziness that typically resolves with continued use. Overall, Hyzaar receives positive evaluations for its efficacy in moderate to severe hypertension management.